192 related articles for article (PubMed ID: 24422369)
1. An update on thalassemia intermedia.
Maakaron JE; Cappellini MD; Taher AT
J Med Liban; 2013; 61(3):175-82. PubMed ID: 24422369
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
3. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
4. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
5. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
6. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
7. Revisiting beta thalassemia intermedia: past, present, and future prospects.
Ben Salah N; Bou-Fakhredin R; Mellouli F; Taher AT
Hematology; 2017 Dec; 22(10):607-616. PubMed ID: 28589785
[TBL] [Abstract][Full Text] [Related]
8. Beta-thalassemia.
Rund D; Rachmilewitz E
N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
[No Abstract] [Full Text] [Related]
9. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
10. Retinal abnormalities in β-thalassemia major.
Bhoiwala DL; Dunaief JL
Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for diagnosis and management of Beta-thalassemia intermedia.
Karimi M; Cohan N; De Sanctis V; Mallat NS; Taher A
Pediatr Hematol Oncol; 2014 Oct; 31(7):583-96. PubMed ID: 25247665
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
13. New strategies in the treatment of the thalassemias.
Schrier SL; Angelucci E
Annu Rev Med; 2005; 56():157-71. PubMed ID: 15660507
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
[TBL] [Abstract][Full Text] [Related]
16. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
17. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Angelucci E; Pilo F
Ann N Y Acad Sci; 2016 Mar; 1368(1):115-21. PubMed ID: 26999450
[TBL] [Abstract][Full Text] [Related]
18. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of β thalassaemia intermedia.
Taher AT; Musallam KM; Cappellini MD; Weatherall DJ
Br J Haematol; 2011 Mar; 152(5):512-23. PubMed ID: 21250971
[TBL] [Abstract][Full Text] [Related]
20. Thalassemia.
Aydinok Y
Hematology; 2012 Apr; 17 Suppl 1():S28-31. PubMed ID: 22507773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
